SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI)

MLA

Lundin, Magnus, et al. SOdium-Glucose CO-Transporter Inhibition in Patients with Newly Detected Glucose Abnormalities and a Recent Myocardial Infarction (SOCOGAMI). 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1372250754&authtype=sso&custid=ns315887.

APA

Lundin, M., Ferrannini, G., Mellbin, L., Johansson, I., Norhammar, A., Näsman, P., Shahim, B., Smetana, S., Venkateshvaran, A., Wang, A., Sorensson, P., & Ryden, L. (2022). SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI).

Chicago

Lundin, Magnus, Giulia Ferrannini, Linda Mellbin, Isabelle Johansson, Anna Norhammar, Per Näsman, Bahira Shahim, et al. 2022. “SOdium-Glucose CO-Transporter Inhibition in Patients with Newly Detected Glucose Abnormalities and a Recent Myocardial Infarction (SOCOGAMI).” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1372250754&authtype=sso&custid=ns315887.